Retina Research Institute of Texas | Abilene, TX

Research site

Site insights

Top conditions

Top treatments

Abicipar Pegol
Sunitinib Malate

Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 62 total trials

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy o...

Diabetic Macular Edema (DME)
Neovascular Age-related Macular Degeneration (NVAMD)
Drug: EYE103

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Macular Degeneration
Geographic Atrophy of the Macula
Drug: AVD-104
Drug: Avacincaptad

This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability an...

Begins enrollment in 1 month
Neovascular Age-related Macular Degeneration (nAMD)
Drug: RBS-001 Solution for intravitreal injection
Drug: Eylea® Solution for intravitreal injection

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This study will demonstrate that tarcocimab 5 mg is superior to sham treatment in participants with moderately severe to severe NPDR.

Non-proliferative Diabetic Retinopathy
Drug: Tarcocimab
Other: Sham injection

This is a multi-centered, open-labeled, single ascending-dose-cohort study to evaluate 4 dosing cohorts of AG-73305 administered by intravitreal inje...

Active, not recruiting
Diabetic Macular Edema
Drug: AG-73305

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) w...

Active, not recruiting
Age-Related Macular Degeneration
Geographic Atrophy
Drug: avacincaptad pegol

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Wet Age-related Macular Degeneration
Genetic: RGX-314 Dose 2
Biological: Aflibercept (EYLEA®)

Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-1...

Neovascular Age-related Macular Degeneration (nAMD)
Drug: OCU-10-C-110 for Injection

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in...

Neovascular Age-related Macular Degeneration (nAMD)
Drug: AR-14034 SR implant lower dose
Drug: AR-14034 SR implant higher dose

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.

Diabetic Macular Edema (DME)
Drug: KHK4951
Drug: Aflibercept Injection

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

Neovascular Age-Related Macular Degeneration (nAMD)
Drug: Aflibercept Injection
Drug: KHK4951

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of supr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: Aflibercept
Drug: CLS-AX

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Uveitic Macular Edema
Other: Sham
Drug: Vamikibart

Trial sponsors

Kodiak Sciences logo
Allergan logo
AbbVie logo
Aerie Pharmaceuticals logo
Boehringer Ingelheim logo
Kyowa Kirin logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems